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Objectives: Increasing multidrug resistance amongst canine pathogenic staphylococci has renewed interest in
topical antibacterial therapy for skin infections in the context of responsible veterinary prescribing. We therefore
determined the activity in vitro of three clinically relevant topical agents and synergism between two of them
against Staphylococcus pseudintermedius and Staphylococcus aureus.
Methods: The MICs of fusidic acid (n¼199), chlorhexidine (n¼198), miconazole (n¼198) and a 1:1
combination of miconazole/chlorhexidine (n¼198) were determined for canine isolates [50 MRSA and 49
methicillin-resistant S. pseudintermedius (MRSP), 50 MSSA and 50 methicillin-susceptible S. pseudintermedius
(MSSP)] collected from the UK and Germany using an agar dilution method (CLSI VET01-A4). Fractional
inhibitory concentration (FIC) indices were calculated to assess the interaction of miconazole with
chlorhexidine.
Results: MICs of each drug/combination were significantly (P,0.0005) higher for S. aureus when compared
with S. pseudintermedius. Most strains (n¼172) had an MIC of fusidic acid of≤0.03 mg/L (MIC≥64 mg/L, n¼5
MRSA). All strains had MICs of chlorhexidine of 0.5–4 mg/L, except for one MRSA (MIC¼8 mg/L). All but four
strains had MICs of miconazole of 1–4 mg/L (MIC¼16 mg/L, n¼3; MIC¼256 mg/L, n¼1). Miconazole/chlor-
hexidine (1:1 ratio) had a synergistic effect against 49/50 MRSA, 31/50 MSSA, 12/49 MRSP and 23/49 MSSP.
Conclusions: Since the majority of these staphylococci, including methicillin-resistant isolates, had MICs that
should be readily exceeded by topical skin application of these agents, their therapeutic efficacy for canine
superficial pyoderma should be assessed. The synergistic interaction shown in vitro supports further clinical
evaluation of miconazole/chlorhexidine combination therapy for staphylococcal infection.
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Introduction
The alarming increase in canine skin infections caused by
methicillin-resistant Staphylococcus pseudintermedius (MRSP) and
MRSA1 paralleled by recognition of zoonotic (and reverse-zoonotic)
infections,2 highlights the urgent need to develop strategies to limit
further emergence of MDR strains. Topical antibacterial therapy can
provide an alternative treatment option formanydogswith bacter-
ial skin infections and thus limit the need for oral antibiotics.3
Licensed drugs include fusidic acid, chlorhexidine and a 1:1 sham-
poo combination of miconazole and chlorhexidine.
Although there is concern in human medicine over reduced effi-
cacy of agents such as chlorhexidine and fusidic acid,4,5 clinical evi-
dence for treatment failure remains inconsistent. Assessment of
resistance is hampered by lack of breakpoint standards for agents
used topically. In dog-derived staphylococci, MICs of fusidic acid,
chlorhexidine and miconazole have been low,6–8 but geographical
differences can be expected.9,10 Since previous MIC studies have
evaluated mainly North American staphylococcal isolates,7,8 we
determined current susceptibility in vitro of dog-derived European
MRSA and MRSP strains and their methicillin-susceptible counter-
parts to fusidic acid, chlorhexidineandmiconazole, and investigated
# The Author 2015. Published by Oxford University Press on behalf of the British Society for Antimicrobial Chemotherapy.
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/
4.0/), which permits unrestricted reuse, distribution, and reproduction in any medium, provided the original work is properly cited.
J Antimicrob Chemother 2015; 70: 2048–2052
doi:10.1093/jac/dkv056 Advance Access publication 5 March 2015
2048
the potential for synergistic interaction between miconazole and
chlorhexidine.
Materials and methods
Bacterial isolates
Coagulase-positive staphylococci [50MRSA and 50MSSA obtained in 2005–
07 and 49 MRSP and 50 methicillin-susceptible S. pseudintermedius (MSSP)
obtained in 2010–13] isolated from dogs were randomly selected from our
collection. Staphylococcus aureus isolates were from canine infections in a
UK-wide study.11 Examples of S. pseudintermedius comprised clinical iso-
lates (Germany, 25 MRSP and 25 MSSP; UK, 24 MRSP) and carriage isolates
(UK, 25 MSSP). Species identification and methicillin resistance were con-
firmed using both phenotypic and genotypic (nuc, mecA) methods.12,13
MIC determination
MICs were determined by agar dilution (CLSI VET01-A4).14 Prior to
MIC determination, strains were subcultured twice on blood agar
base (CM0271, Oxoid) containing 5% sheep blood (TCS Biosciences,
Buckingham, UK) at 358C for 24 h. Stock solutions were prepared at 10×
final concentration in distilled water (fusidic acid sodium salt F0881, chlor-
hexidine digluconate C9394; Sigma-Aldrich Inc.) or 1% DMSO (miconazole
nitrate PHR1163; Sigma), adjusted for drug potency.14 Final concentra-
tions of the active fraction ranged from 0.015 to 2048 mg/L for fusidic
acid and from 0.03 to 256 mg/L for chlorhexidine, miconazole and a 1:1
combination of chlorhexidine and miconazole.14 Discrepancy between
duplicate MICs was accepted provided they varied by only one dilution;
in such cases, the higher value was identified as the final MIC. S. aureus
ATCC 25923, S. aureus ATCC 29663 and S. pseudintermedius LMG 22219
were included for quality control purposes. Three MRSA strains previously
reported with low, medium and high MICs of fusidic acid6 were also
included for comparative purposes.
Fractional inhibitory concentration (FIC) indices
The FIC index was calculated to analyse drug interaction of chlorhexidine
and miconazole when used in the 1:1 combination, using the formula
SFIC¼FICchlorhexidine+FICmiconazole¼ (MICCM/MICC)+ (MICCM/MICM), where
MICC and MICM are the MICs of chlorhexidine and miconazole alone,
respectively, and MICCM is the MIC of the two drugs in combination. An
FIC index of ≤0.5 represented synergy, an FIC index of .4 represented
antagonism and an FIC index of .0.5–4 represented no interaction.15
Statistical analysis
SPSS version 21 (IBM UK Ltd, Portsmouth, UK) was used, with P,0.05 for
significance. Since data were not normally distributed (Shapiro–Wilk test),
the MIC values for different bacterial groups were compared using the
Kruskal–Wallis test. Post hoc comparisons were performed using Mann–
Whitney U-tests with Holm–Bonferroni adjustments.
Results
One MSSP strain failed to grow in studies of MICs of chlorhexidine,
miconazole and miconazole plus chlorhexidine. MICs varied by a
single dilution between replicates on only five occasions.
Fusidic acid
The MICs of fusidic acid amongst the field collection ranged from
≤0.015 to 384 mg/L (median ≤0.015 mg/L); 172 of 199 isolates
had MICs ≤0.03 mg/L and 192 isolates had MICs ≤4 mg/L
(Table 1). Seven isolates had higher MICs of 16–384 mg/L, com-
prising five MRSA (384 mg/L, n¼4; 64 mg/L, n¼1) and single
examples of MSSA and MRSP (both 16 mg/L). Overall, MICs were
higher (P,0.0005) for S. aureus isolates (median 0.03 mg/L,
n¼100) than S. pseudintermedius isolates (median ≤0.015 mg/L,
n¼99), though therewas no significant difference inMICs between
methicillin-susceptible and resistant isolates within each species.
MICs for reference isolates were low (ATCC 25932, 0.03 mg/L;
ATCC 29663 and LMG 22219, ≤0.015 mg/L), as expected. The iso-
lates included for internal comparative purposes had MICs com-
parable to previous determinations [A004, 0.12 (previous) and
0.03 (present) mg/L; A013, 2 and 1 mg/L; and A016, .128 and
384 mg/L].
Chlorhexidine
The MICs of chlorhexidine ranged from 0.5 to 8 mg/L (median
2 mg/L; Table 1). The MICs for MRSA (n¼50) were remarkably uni-
form, with 49 out of 50 isolates having an MIC of 4 mg/L; these
values were higher (P,0.0005) than those for all other bacterial
groups. Overall, the S. aureus isolates (median 4 mg/L, n¼100)
had higher MICs than the S. pseudintermedius isolates (median
1 mg/L, n¼98) (P,0.0005). The MICs did not vary significantly
between MRSP (n¼49) and MSSP (n¼49) (P¼0.055).
Miconazole
The MICs of miconazole ranged from 1 to 256 mg/L (median
2 mg/L); 175 of 198 isolates had MICs of 1 or 2 mg/L and 19
had MICs of 4 mg/L (Table 1). Four isolates had higher MICs, com-
prising single examples of MRSA, MSSA and MSSP with MICs of
16 mg/L and one MSSAwith anMICof 256 mg/L. S. aureus isolates
(median 2 mg/L, n¼100) had higher MICs than S. pseudinterme-
dius isolates (median 1 mg/L, n¼98) (P,0.0005). There was no
difference (P¼0.415) in MIC between the MRSA and MSSA groups;
however, the MRSP group (median 2 mg/L, n¼49) had a signifi-
cantly (P,0.0005) higher MIC than the MSSP group (median
1 mg/L, n¼49).
Miconazole and chlorhexidine in combination
The MICs of the 1:1 combination of miconazole and chlorhexidine
ranged from 0.25 to 8 mg/L (median 0.5 mg/L; Table 1); 190 of
198 isolates had an MIC of 0.25 or 0.5 mg/L and all but one
MSSA isolate had an MIC of ≤2 mg/L. The MICs for the S. aureus
isolates (median 0.5 mg/L) exceeded (P,0.0005) those for the
S. pseudintermedius isolates (median 0.5 mg/L), and the MICs
for the MSSP group (median 0.25 mg/L) were lower (P,0.0005)
than for the other three groups. The MSSA isolate whose micona-
zole MICwas 256 mg/L had an MIC of 8 mg/L for the combination.
A synergistic interaction between miconazole and chlorhexi-
dine (FIC index≤0.5) was observed for 80 out of 100 S. aureus iso-
lates and 35 out of 98 S. pseudintermedius isolates (Table 2).
Antagonistic interactions were not observed; the other strains
fell into the ‘no interaction’ group as defined by Odds.15 EUCAST
guidelines16 consider that FIC indices from 0.5 to 1 indicate addi-
tivity; by this definition a further 62 strains demonstrated additive
effects (MRSA, n¼1; MSSA, n¼18; MRSP, n¼19; MSSP, n¼24).
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Table 1. MICs of fusidic acid for 199 coagulase-positive staphylococcal isolates from dogs and MICs of chlorhexidine, miconazole and a 1:1 combination of miconazole/chlorhexidine for
198 coagulase-positive staphylococcal isolates from dogs
Drug
Bacterial
type
MIC (mg/L)
Median (IQR) MIC50 MIC90≤0.015 (≤)0.03 0.06 0.125 0.25 0.5 1 2 4 8 16 32 64 128 256 384
Fusidic acid MRSA 8 34 0 0 3 0 0 0 0 0 0 0 1 0 0 4 0.03 (0.03–0.03) 0.03 0.25
MSSA 24 13 0 0 1 1 6 2 2 0 1 0 0 0 0 0 0.03 (≤0.015–0.3125) 0.03 1
MRSP 46 1 0 0 0 0 1 0 0 0 1 0 0 0 0 0 ≤0.015 (≤0.015 to ≤0.015) ≤0.015 ≤0.015
MSSP 41 5 0 0 0 0 0 1 3 0 0 0 0 0 0 0 ≤0.015 (≤0.015 to ≤0.015) ≤0.015 0.03
Chlorhexidine MRSA not tested 0 0 0 0 0 0 0 49 1 0 0 0 0 0 0 4 (4–4) 4 4
MSSA not tested 0 0 0 0 1 22 22 5 0 0 0 0 0 0 0 2 (1–2) 2 2
MRSP not tested 0 0 0 0 19 10 18 2 0 0 0 0 0 0 0 1 (0.5–2) 1 2
MSSP not tested 0 0 0 0 21 25 0 3 0 0 0 0 0 0 0 1 (0.5–1) 1 1
Miconazole MRSA not tested 0 0 0 0 0 0 43 6 0 1 0 0 0 0 0 2 (2–2) 2 4
MSSA not tested 0 0 0 0 0 4 32 12 0 1 0 0 0 1 0 2 (2–4) 2 4
MRSP not tested 0 0 0 0 0 22 27 0 0 0 0 0 0 0 0 2 (1–2) 2 2
MSSP not tested 0 0 0 0 0 43 4 1 0 1 0 0 0 0 0 1 (1–1) 1 2
Miconazole plus
chlorhexidine
(1:1)
MRSA not tested 0 0 0 0 45 4 1 0 0 0 0 0 0 0 0 0.5 (0.5–0.5) 0.5 0.5
MSSA not tested 0 0 0 7 41 0 1 0 1 0 0 0 0 0 0 0.5 (0.5–0.5) 0.5 0.5
MRSP not tested 0 0 0 2 47 0 0 0 0 0 0 0 0 0 0 0.5 (0.5–0.5) 0.5 0.5
MSSP not tested 0 0 0 40 8 0 1 0 0 0 0 0 0 0 0 0.25 (0.25–0.25) 0.25 0.5
MRSA, n¼50; MSSA, n¼50; MRSP, n¼49; and MSSP, n¼50 for fusidic acid and n¼49 for chlorhexidine, miconazole and miconazole plus chlorhexidine.
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Discussion
The low MICs of fusidic acid, miconazole and chlorhexidine for the
great majority of these canine staphylococcal isolates in vitro pro-
vide strong support for their use topically in clinical cases of sur-
face and superficial pyoderma, including cases caused by
methicillin-resistant bacteria.
The interpretation of MIC values in the context of susceptibility/
resistance is hindered by the absence of defined breakpoints; whilst
EUCAST guidelines indicate a value of 2 mg/L for fusidic acid when
used against S. aureus, this is of questionable value for canine skin
infections treated topically rather than systemically.
The prevalence of high fusidic acid MICs for human-derived
S. aureus appears related to geographical variation in prescribing
practice in humanmedicine;17 10.7% of human-derived European
S. aureus had MICs≥2 mg/L9 compared with only 0.3% of isolates
from North America, where fusidic acid usage is infrequent.10 The
comparable frequency of fusidic acid MICs ≥2 mg/L amongst our
European canine MRSA isolates (10.0%) is perhaps not surprising
since these strains likely originate from human sources.6 The strik-
ingly uniform MICs of chlorhexidine, almost exclusively in the nar-
row range of 0.5–4 mg/L, are remarkably similar to those reported
previously for MRSA isolates from human sources worldwide.18
Similarly, the MICs ofmiconazole in the present study are compar-
able to those in previous reports indicating good efficacy against
staphylococci.8
The frequent synergistic activity of the combination of chlor-
hexidine and miconazole indicates potential clinical value as a
combination treatment in dogs, especially as they lack a critical
role in human medicine.
Monitoring for the presence, and potential for transfer, of
resistance between populations of MRSA on dogs and humans,
and between canine S. pseudintermedius and human S. aureus
strains is warranted. Genetic studies are also required to explain
the rare higher MICs that were identified in individual isolates.
Previous authors have reported maximum values in the order of
16 mg/L miconazole for S. aureus and 8 mg/L fusidic acid for
S. pseudintermedius; the value of 16 mg/L fusidic acid seen for a
single MRSP strainmight correspond to ‘low-level fusidic acid resist-
ance’17 and explanation is needed for the single high MIC of mico-
nazole of 256 mg/L.
This study provides further evidence to support topical therap-
ies as an alternative to systemic antibacterial drugs in superficial
pyoderma. Further work is needed to confirm the clinical efficacy
of these topical treatments.
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